rs3751143 — P2RX7 Glu496Ala

Loss-of-function variant in the P2X7 receptor that reduces inflammatory response and may modulate pain sensitivity

See your personal result for P2RX7

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

P2RX7 Glu496Ala — A Loss-of-Function Variant with Complex Effects on Pain and Inflammation

The P2X7 receptor is an ATP-gated ion channel11 ATP-gated ion channel
The receptor opens in response to high concentrations of extracellular ATP, typically released during tissue damage or cell death expressed primarily on immune cells, particularly microglia in the central nervous system. When activated by high concentrations of extracellular ATP—a danger signal released during tissue damage—P2X7 triggers a cascade of inflammatory responses. The Glu496Ala variant (rs3751143, also known as 1513A>C) is a well-characterized loss-of-function polymorphism22 well-characterized loss-of-function polymorphism
First described in 2001 by Gu et al., showing the variant leads to non-functional receptors that dramatically reduces receptor activity. This single amino acid change from glutamic acid to alanine at position 496 impairs both channel and pore function33 impairs both channel and pore function
Studies show 70-90% reduction in ATP-induced responses in homozygous carriers, affecting inflammatory signaling and pain processing in ways that can be both protective and detrimental depending on the clinical context.

The Mechanism

The Glu496Ala substitution occurs in the C-terminal intracellular domain44 C-terminal intracellular domain
This region is critical for receptor trafficking to the cell membrane and pore formation of the P2X7 receptor. This region is essential for proper receptor function, influencing both ATP binding affinity and the formation of the large membrane pore that allows passage of molecules up to 900 daltons. In homozygous CC individuals, the mutant receptors show severely reduced cell surface expression and near-complete loss of ATP-induced channel opening55 near-complete loss of ATP-induced channel opening
Homozygous carriers show 9-fold lower ATP-induced ion efflux compared to wild-type. Heterozygous AC carriers express approximately half the functional receptor protein compared to AA wild-type individuals, resulting in intermediate phenotypes. The loss of function translates to impaired potassium efflux, reduced inflammasome activation66 potassium efflux, reduced inflammasome activation
The NLRP3 inflammasome requires P2X7 activation for assembly and cytokine maturation, and delayed release of the pro-inflammatory cytokine IL-1β from immune cells in response to danger signals.

The Evidence

The clinical consequences of rs3751143 are context-dependent. In chronic pain conditions77 chronic pain conditions
Study of diabetic neuropathic pain patients found loss-of-function carriers had lower pain scores, the C allele appears protective. A 2014 study of diabetic peripheral neuropathic pain found that while gain-of-function variants in P2RX7 were associated with higher pain intensity in females, the Glu496Ala loss-of-function variant showed the opposite pattern. This aligns with extensive animal research demonstrating that P2X7 knockout mice show reduced pain hypersensitivity88 P2X7 knockout mice show reduced pain hypersensitivity
Disruption of P2X7 abolishes chronic inflammatory and neuropathic pain in mice in models of nerve injury and chronic inflammation. The receptor's role in activating spinal microglia—the immune cells that amplify pain signals in the central nervous system—explains this protective effect.

For cardiovascular disease99 cardiovascular disease
Meta-analysis of ischemic heart disease and stroke in 14,000+ individuals, the loss-of-function variant also shows benefit. A 2012 study found the C allele significantly associated with reduced risk of ischemic stroke (OR 0.89, 95% CI 0.81-0.97, P=0.012) and decreased ischemic heart disease risk in smokers. The mechanism likely involves reduced inflammatory activation1010 reduced inflammatory activation
P2X7 drives inflammatory atherosclerosis through cytokine release from vascular immune cells in atherosclerotic plaques and vascular inflammation.

However, the dampened immune response creates vulnerabilities. In infectious disease1111 infectious disease
Study of 163 chronic Q fever patients over median 42-month follow-up, the CC genotype was associated with a 2.4-fold increased risk of treatment failure (SHR 2.42, 95% CI 1.16-5.05). The P2X7 receptor is crucial for immune cells to kill intracellular pathogens like Coxiella burnetii (the causative agent of Q fever), Mycobacterium tuberculosis1212 Mycobacterium tuberculosis
Meta-analysis showing increased tuberculosis susceptibility with loss-of-function P2X7 variants, and Toxoplasma gondii. Loss-of-function impairs this pathogen clearance mechanism.

An interesting protective aspect emerges in acute inflammatory conditions1313 acute inflammatory conditions
Ex vivo study showing CC carriers had reduced cytotoxicity at high ATP concentrations. A 2012 study using whole blood models found that carriers of Glu496Ala were protected against the cytotoxic effects of high ATP levels during severe inflammation, while still maintaining some IL-1β release capacity—suggesting a potentially beneficial buffering effect during cytokine storms.

Practical Implications

For pain management, carriers of the C allele may experience naturally lower pain sensitivity, particularly in chronic inflammatory and neuropathic pain states1414 chronic inflammatory and neuropathic pain states
P2X7 expressed in spinal microglia drives central sensitization in chronic pain. This doesn't mean you're immune to pain, but the threshold for developing chronic pain after injury may be higher. If you do develop chronic pain, you might respond differently to treatments targeting inflammatory pathways.

The infectious disease implications are more concerning for CC homozygotes. While the absolute risk of problematic infections remains low1515 absolute risk of problematic infections remains low
Population studies show no major health burden despite ~3% CC frequency in most populations, awareness is important if you develop infections with intracellular bacteria (Q fever, tuberculosis, certain atypical infections). These may require more aggressive or prolonged antibiotic therapy. The cardiovascular protection is a modest but real benefit—the ~11% reduction in ischemic stroke risk translates to meaningful population-level protection.

The reduced inflammatory tone1616 reduced inflammatory tone
Carriers show lower baseline inflammatory cytokine production associated with this variant may also influence response to inflammatory triggers, vaccines, and immune-mediated conditions. Some evidence suggests carriers might have reduced vaccine-induced inflammatory responses, though protection is typically maintained through other immune pathways.

Interactions

Rs3751143 is one of several functionally significant variants in the highly polymorphic P2RX7 gene. Two gain-of-function variants, rs208294 (His155Tyr) and rs1718119 (Ala348Thr), have opposite effects—increasing P2X7 activity and pain sensitivity. Another variant, rs7958311 (Arg270His), has been more consistently associated with chronic pain conditions including fibromyalgia and irritable bowel syndrome, with a unique combined gain-of-function in channel opening but loss-of-function in pore formation. Individuals carrying both loss-of-function and gain-of-function P2RX7 variants may have complex phenotypes where effects partially cancel out. The net impact on pain sensitivity, inflammation, and immune function depends on which variants are present and their relative functional effects. Additionally, P2X7 function interacts with other purinergic receptors (P2X4, P2Y receptors) and inflammatory pathways (NLRP3 inflammasome, IL-1 signaling) that modulate its clinical effects.

Genotype Interpretations

What each possible genotype means for this variant.

AA Normal P2X7 Function Normal

Fully functional P2X7 receptor with standard inflammatory and pain responses

You have two copies of the ancestral allele, which codes for the original glutamic acid at position 496. Your P2X7 receptors function normally, providing full capacity for ATP-induced inflammatory signaling and immune responses. This is the most common genotype, found in approximately 76% of people overall. Your immune system has standard capacity to respond to infections, particularly those caused by intracellular bacteria, and your pain signaling operates through typical pathways.

AC Reduced P2X7 Function Intermediate

One functional and one non-functional P2X7 allele, resulting in intermediate inflammatory and pain responses

The heterozygous state produces a mild reduction in P2X7-mediated functions. Studies show that AC individuals have intermediate levels of ATP-induced potassium efflux and IL-1β release—roughly halfway between AA and CC carriers. In the context of pain, you may have a slightly higher threshold for developing chronic pain after injury, and if you do develop neuropathic or inflammatory pain conditions, your baseline pain intensity may be somewhat lower than full function carriers. The cardiovascular protective effect appears to follow a dose-dependent pattern, so you likely have some reduced risk of inflammatory cardiovascular events, though less pronounced than CC carriers. For infectious disease, your immune system retains substantial pathogen-killing capacity, but may require standard or slightly extended treatment courses for difficult intracellular infections.

CC Loss of P2X7 Function Reduced

Two copies of the loss-of-function allele, resulting in severely reduced P2X7 activity

The homozygous loss-of-function state produces near-complete impairment of P2X7-mediated inflammatory signaling. Your immune cells release substantially less IL-1β and other inflammatory cytokines in response to danger signals. In pain conditions, this creates meaningful protection—studies show that individuals with complete P2X7 loss-of-function have significantly lower pain scores in diabetic neuropathy and other chronic pain states. The mechanism involves reduced microglial activation in the spinal cord, which normally amplifies pain signals from the periphery. For cardiovascular health, your reduced inflammatory tone translates to approximately 11% lower risk of ischemic stroke, likely through decreased inflammatory damage to blood vessels and atherosclerotic plaques. The infectious disease vulnerability is most significant for intracellular pathogens—your immune cells are less efficient at killing bacteria that hide inside cells. This doesn't mean you'll get more infections overall, but when you do get certain types (Q fever, tuberculosis, toxoplasmosis, some atypical infections), they may be harder to clear. Treatment failure rates can be 2-3 times higher than in normal P2X7 function individuals. The protective effect against cytotoxicity during extreme inflammation (sepsis, cytokine storms) may be clinically relevant in severe illness.